What is Asensus Surgical?
Asensus Surgical is pioneering a new era of Performance-Guided Surgery by integrating digital intelligence into the surgical workflow. Their Senhance Surgical System, powered by the Intelligent Surgical Unit (ISU), aims to increase surgeon control and minimize variability in procedures. By incorporating machine vision, augmented intelligence, and deep learning, the company seeks to address critical clinical, cognitive, and economic challenges in modern healthcare, ultimately striving for superior patient outcomes and improved value-based care. The company's focus on digital laparoscopy and advanced surgical technologies positions it within the rapidly evolving medtech landscape.
How much funding has Asensus Surgical raised?
Asensus Surgical has raised a total of $469M across 19 funding rounds:
Stock Offering
$25M
Multiple Rounds
$45.4M
Debt
$40M
Stock Offering
$23.7M
Multiple Rounds
$55.7M
Share Placement
$31.3M
Other Financing Round
$20M
Stock Issuance/Offering (2016): $25M supported by Lincoln Park Capital
Private Equity (2017): $5.2M featuring SOFAR S.p.A
Stock Issuance/Offering (2017): $23.2M backed by Undisclosed
Debt (2017): $17M with participation from Innovatus Capital Partners
Debt (2018): $40M led by Hercules Capital
Stock Issuance/Offering (2019): $23.7M supported by Undisclosed
Stock Issuance/Offering (2020): $25M featuring Lincoln Park Capital
Stock Issuance/Offering (2020): $15M backed by Undisclosed
Debt (2020): $2M with participation from PPP
Stock Issuance/Offering (2020): $13.7M led by Undisclosed
Share Placement (2021): $31.3M, investors not publicly disclosed
Other Financing Round (2024): $20M featuring KARL STORZ
Key Investors in Asensus Surgical
KARL STORZ
KARL STORZ is a leading provider of reusable endoscopy and medical technology products, known for its extensive range of surgical instruments and commitment to advancing medical informatics and minimally invasive surgical techniques.
Hercules Capital
Hercules Capital is a specialty finance company that provides debt financing and equity capital to technology and venture-backed companies, often supporting growth-stage companies with their funding needs.
SOFAR S.p.A
SOFAR S.p.A is an Italian pharmaceutical company with a focus on respiratory diseases and other therapeutic areas, suggesting a potential interest in medical device innovation that complements healthcare solutions.
What's next for Asensus Surgical?
The recent major strategic investment signals a pivotal moment for Asensus Surgical, likely enabling accelerated development and broader market penetration of its Performance-Guided Surgery solutions. This capital infusion is expected to fuel further innovation in their AI-driven surgical technologies and expand the reach of the Senhance Surgical System. As the company continues to build upon its foundation of digital laparoscopy, the strategic backing suggests a focus on scaling operations, forging key partnerships, and solidifying its position as a leader in transforming surgical performance through advanced digital tools and clinical intelligence.
See full Asensus Surgical company page
